Table 3

Results of the base case model after 3 years

% progress to ESRD (95%CI)

Life years lived (95%CI)

Costs (€) (95%CI)

Moxonidine

7.5% (3.5–12.7)

2.950 (2.937–2.959)

€9,858 (5,501–16,174)

Nitrendipine

38.9% (31.8–45.8)

2.907 (2.882–2.927)

€37,472 (27,957–49,478)

Littlewood et al. BMC Nephrology 2007 8:9   doi:10.1186/1471-2369-8-9